CIK 0001650648
- Non-accelerated filer
- Smaller reporting company
4D Molecular Therapeutics, Inc.
Sign in to watch- Ticker
- FDMT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 473506994
- Phone
- +1 510-505-2680
- Business address
- 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
- Former names
- 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,704,701
- in 6 filings, $2.7M under 10b5-1 plans
Net −$2,704,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-05 | Kirn David See Remarks | Sale 10b5-1 | −58,061 | $12.92 | $750K | 709,425 |
| 2026-10-05 | Kirn David See Remarks | Sale 10b5-1 | −272 | $13.61 | $4K | 709,153 |
| 2026-09-14 | Kirn David See Remarks | Sale 10b5-1 | −58,333 | $13.90 | $811K | 767,486 |
| 2026-08-19 | Kirn David See Remarks | Option exercise 10b5-1 | +50,000 | $4.14 | $207K | 894,895 |
| 2026-08-19 | Kirn David See Remarks | Sale 10b5-1 | −43,149 | $15.36 | $663K | 851,746 |
| 2026-08-19 | Kirn David See Remarks | Sale 10b5-1 | −25,927 | $16.42 | $426K | 825,819 |
| 2026-08-19 | Kirn David See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,000 | 217,500 | ||
| 2026-08-04 | Kirn David See Remarks | Sale 10b5-1 | −26,842 | $10.23 | $275K | 844,895 |
| 2026-08-03 | Kirn David See Remarks | Sale 10b5-1 | −12,415 | $10.05 | $125K | 871,737 |
| 2026-07-10 | Kirn David See Remarks | Sale 10b5-1 | −15,283 | $12.01 | $184K | 884,594 |
| 2026-07-10 | Kirn David See Remarks | Sale 10b5-1 | −442 | $12.84 | $6K | 884,152 |
| 2026-07-09 | Kirn David See Remarks | Sale 10b5-1 | −42,608 | $12.87 | $548K | 899,877 |
| 2026-06-22 | Kirn David See Remarks | Sale 10b5-1 | −114,746 | $10.47 | $1.2M | 942,485 |
| 2026-06-01 | Kirn David See Remarks | Sale 10b5-1 | −1,922 | $10.02 | $19K | 1,057,231 |
| 2026-03-25 | Kirn David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +750,000 | 750,000 | ||
| 2025-03-06 | Kirn David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +267,500 | 267,500 | ||
| 2024-07-10 | Kirn David Chief Executive Officer | Option exercise 10b5-1 | +11,653 | $14.42 | $168K | 1,070,806 |
| 2024-07-10 | Kirn David Chief Executive Officer | Option exercise 10b5-1 | +1,270 | $15.78 | $20K | 1,072,076 |
| 2024-07-10 | Kirn David Chief Executive Officer | Sale 10b5-1 | −12,923 | $22.49 | $291K | 1,059,153 |
| 2024-07-10 | Kirn David Chief Executive Officer | Option exercise · Stock Option (Right To Buy) 10b5-1 | −11,653 | 565,417 |
Page 1 of 3 · 46 trades